Rhizen announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. Rhizen also announced positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.

Alembic Pharmaceuticals through its wholly owned subsidiary holds 50% ownership in Rhizen.